New oral anticoagulants: Clinical indications, monitoring and treatment of acute bleeding complications

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 6, 2014, Pages 651-659

  Fenger Eriksen, C ^a   Munster A M ^b   Grove, E L ^c  

^a VIBORG HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE; THROMBIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG BLOOD LEVEL; DRUG MONITORING; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; REGIONAL ANESTHESIA; REVIEW; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING TEST; CHEMICALLY INDUCED; HEMORRHAGE; HEMOSTASIS; THROMBOEMBOLISM; THROMBOPHILIA;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR XA INHIBITORS; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 84903135364     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12319     Document Type: Review

References (44)

1. Ferland G,. The discovery of vitamin K and its clinical applications. Ann Nutr Metab 2012; 61: 213-218.
2. Franchini M, Mannucci PM,. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med 2012; 23: 692-695.
3. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM,. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
7. Harder S, Graff J,. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013; 69: 1617-1633.
8. Merli GJ,. New oral antithrombotic agents for the prevention of deep venous thrombosis and pulmonary embolism in orthopedic surgery. Orthopedics 2010; 33: 27-32.
9. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S,. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
10. Poulsen BK, Grove EL, Husted SE,. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72: 1739-1753.
11. Kernan L, Ito S, Shirazi F, Boesen K,. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) 2012; 50: 571-573.
12. Béné J, Saïd W, Rannou M, Deheul S, Coupe P, Gautier S,. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012; 46: e14.
13. Wychowski MK, Kouides PA,. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46: e10.
14. Cano EL, Miyares MA,. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012; 10: 160-163.
15. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A,. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
16. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M,. Population model of the pharmacokinetics and pharmaco dynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344. (Pubitemid 46895052)
17. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F,. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
18. Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M,. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010; 88: 375-382.
19. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL, Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
20. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL,. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
21. Barrett YC, Wang Z, Frost C, Shenker A,. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
22. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013; 106: 382-393.
23. Weitz JI, Quinlan DJ, Eikelboom JW,. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126: 2428-2432.
24. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Spahn DR, the STOP the Bleeding Campaign. The STOP the Bleeding Campaign. Crit Care 2013; 17: 136.
25. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Görlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø AJ, Wouters P, Wyffels P,. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382.
26. Zhou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, Veltkamp R,. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
27. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R,. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
28. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T,. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
29. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U,. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
30. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
31. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G,. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
32. Miesbach W, Seifried E,. New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108: 625-632.
33. Díaz MQ, Borobia AM, Núñez MA, Virto AM, Fabra S, Casado MS, García-Erce JA, Samama CM,. Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department. Haematologica 2013; 98: e143-144.
34. Le Saché F, Le Bonniec B, Gaussem P, Dizier B, Tagzirt M, Godier A, Emmerich J, Samama CM,. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit. Br J Anaesth 2012; 108: 586-593.
35. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM,. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
36. Levi M, Levy JH, Andersen HF, Truloff D,. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
37. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J,. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
38. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
39. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R,. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.
40. Fawole A, Daw HA, Crowther MA,. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013; 80: 443-451.
41. Stangier J, Rathgen K, Stähle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
42. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW,. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
43. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM, European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999-1015.
44. Sinnaeve PR, Van de Werf F,. Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets. Circulation 2013; 127: 566-568.